|
Beijing, Oct. 1st, 2022 — Neoletix Biotechnology Co., LTD (Neoletix) announced today that it has entered into an exclusive license agreement with Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd... Zhuangya Biotechnology Co.,LTD (Neoletix) announced that NX01, Recombinant Human Coagulation Factor VIII for Injection, the first biologics based on Neoletix's proprietary protein expression techno... https://www.prnewswire.com/news-releases/genscript-probio-and-neoletix-signed-a-letter-of-intent-on-clinical-and-commercial-production-of-recombinant-human-coagulation-factor-viii-301302719.html?tc... https://hemophilianewstoday.com/2021/06/07/genscript-probio-neoletix-partner-produce-man-made-fviii-hemophilia-a-china https://en.prnasia.com/releases/global/genscript-probio-and-neoletix-announce-successful-completion-of-200-liter-gmp-production-runs-of-recombinant-coagulation-fviii-based-on-a-novel-production-tec... |
